Phase II trial of perioperative gemcitabine and cisplatin chemotherapy in resected pleural mesothelioma (2)
Phase II trial of perioperative gemcitabine and cisplatin chemotherapy in resected
pleural mesothelioma
The primary objective of the study is to determine the progression-free survival
and overall survival of patients receiving perioperative (before surgery and/or
after surgery) chemotherapy followed by adjuvant (after surgery) radiation therapy
for resected pleural mesothelioma. The secondary objectives are to assess the toxicity
of perioperative cisplatin and gemcitabine chemotherapy in this patient population.
For patients referred prior to surgery: Chemotherapy will be given for 6 weeks followed
by surgical removal of disease-affected lung tissue. This will be followed by another
6 weeks of chemotherapy, radiation therapy and another 6 weeks of chemotherapy.
For patients referred after surgery: Surgical removal of disease-affected lung tissue
will be followed by 9 weeks of chemotherapy. This will be followed by radiation
therapy and another 9 weeks of chemotherapy.
Patient Inclusion/Exclusion Criteria:
Patients will be adults who have histologically confirmed malignant pleural mesothelioma
and will have received no prior chemotherapeutic regimens.
Contact:
Mary Hesdorffer, RN, BSN, Clinical Research Nurse
Columbia-Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
161 Fort Washington Avenue
New York, NY
Telephone: 212-305-1252
Fax: 212-305-6891
Email: mp317@columbia.edu
